InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Global X S&P Biotech ETF (ASX: CURE) - Announcements

Current share price for CURE : $73.790 1.58 (2.10%)+

Global X S&P Biotech ETF (CURE) is an Exchange Traded Fund - commonly known as an ETF. For more details about how ETFs work, feel free to check out our What is an ETF? overview. The Global X S&P Biotech ETF (CURE) seeks to invest in companies that stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Latest company announcements for Global X S&P Biotech ETF (CURE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$48 Update - Dividend/Distribution 1 Jul 2022 6:50PM $36.530 $73.790 risen by 102%
$48 ETFS Units on Issue June 2022 1 Jul 2022 6:01PM $36.530 $73.790 risen by 102%
$48 Updated Estimated Distribution Announcement - Jun 2022 30 Jun 2022 9:52AM $36.920 $73.790 risen by 99.86%
$48 Estimated Distribution Announcement - June 2022 24 Jun 2022 5:11PM $38.030 $73.790 risen by 94.03%
$48 Change of ownership and control of responsible entity 15 Jun 2022 12:21PM $31.680 $73.790 risen by 132.92%
$48 ETFS Units on Issue May 2022 3 Jun 2022 11:34AM $32.400 $73.790 risen by 127.75%
$48 Replacement PDS dated 9 May 2022 9 May 2022 8:49AM $35.680 $73.790 risen by 106.81%
$48 ETFS Units on Issue April 2022 2 May 2022 6:01PM $36.200 $73.790 risen by 103.84%
$48 ETFS Units on Issue March 2022 1 Apr 2022 4:15PM $41.350 $73.790 risen by 78.45%
$48 CURE Half Year Accounts 16 Mar 2022 8:51AM $38.990 $73.790 risen by 89.25%
$48 ETFS Units on Issue February 2022 1 Mar 2022 10:26AM $42.240 $73.790 risen by 74.69%
$48 ETFS Units on Issue January 2022 1 Feb 2022 5:01PM $45.580 $73.790 risen by 61.89%
$48 ETFS Units on Issue December 2021 5 Jan 2022 8:34AM $55.190 $73.790 risen by 33.70%
$48 ETFS Units on Issue November 2021 1 Dec 2021 7:54PM $56.410 $73.790 risen by 30.81%
$48 ETFS Units on Issue October 2021 2 Nov 2021 11:06AM $59.000 $73.790 risen by 25.07%
$48 CURE Annual Financial Report 4 Oct 2021 11:37AM $59.560 $73.790 risen by 23.89%
$48 ETFS Units on Issue September 2021 1 Oct 2021 8:27AM $59.920 $73.790 risen by 23.15%
$48 ETFS Units on Issue August 2021 1 Sep 2021 12:45PM $62.580 $73.790 risen by 17.91%
$48 ETFS Units on Issue Jul 2021 2 Aug 2021 12:27PM $57.900 $73.790 risen by 27.44%
$48 ETFS Units on Issue Jun 2021 2 Jul 2021 8:19AM $62.420 $73.790 risen by 18.22%
$48 Update - Dividend/Distribution - CURE 1 Jul 2021 7:13PM $62.420 $73.790 risen by 18.22%
$48 Update - Dividend/Distribution - CURE 30 Jun 2021 9:06AM $68.920 $73.790 risen by 7.07%
$48 Update - Dividend/Distribution - CURE 30 Jun 2021 8:19AM $68.920 $73.790 risen by 7.07%
$48 Dividend/Distribution - CURE 24 Jun 2021 6:14PM $67.340 $73.790 risen by 9.58%
$48 ETFS Units on Issue May 29021 1 Jun 2021 4:06PM $62.670 $73.790 risen by 17.74%

101 - 125 of 150 results

Page 5 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.